Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Vaccines against Emerging Infectious Diseases
share announcement

Vaccines against Emerging Infectious Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 7402

Special Issue Editors

Dr. Awadalkareem Adam

E-Mail Website
Guest Editor
Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77550, USA
Interests: vaccine development against emerging and re-emerging RNA viruses; the study of B cell and T cell responses to viral infection and vaccination
Dr. Xuping Xie

E-Mail Website
Guest Editor
Biochemistry & Molecular Biology, The University of Texas Medical Branch, Galveston, TX 77550, USA
Interests: understanding the molecular basis of positive-sense RNA viruses, antiviral drug discovery, and viral vaccine development

Special Issue Information

Dear Colleagues,

In recent decades, several emerging and re-emerging RNA virus-induced infectious viral diseases, such as Ebola hemorrhagic fever, Marburg hemorrhagic fever, Lassa fever, Nipah fever, Rift Valley Fever, dengue fever, yellow fever, West Nile fever, congenital Zika syndrome, as well as Chikungunya fever, swine flu, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the more recent COVID-19 complications, have threatened human and animal health and had significant impacts on public health and economies worldwide. Vaccination continues to be the most effective global strategy for the control and prevention of infectious diseases in humans and animals. Despite continuous efforts to develop effective vaccines, licensed vaccines are not yet available for the control of many of these emerging and re-emerging viruses. Therefore, there is an urgent need to develop safe and effective vaccines to prevent emerging infectious viral diseases.

This Special Issue is titled “Virus Vaccines and Emerging Infectious Diseases”. We would like to invite original research articles, as well as reviews, on topics related to vaccine development, including vaccine discovery, novel vaccine delivery platform, vaccine safety, vaccine formulation, novel vaccine adjuvant, immunogenicity and vaccinology studies, immunological responses to vaccine targets, immune correlates of vaccine-induced host protection, and preclinical and clinical studies of vaccines.

Dr. Awadalkareem Adam
Dr. Xuping Xie
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • emerging viruses
  • vaccine development
  • veterinary vaccine
  • human vaccine
  • emerging infectious diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 960 KiB  
Article
Protective Effects from Prior Pneumococcal Vaccination in Patients with Chronic Airway Diseases during Hospitalization for Influenza—A Territory-Wide Study
by Wang-Chun Kwok, David Christopher Lung, Terence Chi-Chun Tam, Desmond Yat-Hin Yap, Ting-Fung Ma, Chung-Ki Tsui, Ru Zhang, David Chi-Leung Lam, Mary Sau-Man Ip and James Chung-Man Ho
Vaccines 2024, 12(7), 704; https://doi.org/10.3390/vaccines12070704 - 23 Jun 2024
Viewed by 1052
Abstract
Influenza is an important respiratory viral pathogen in adults, with secondary bacterial pneumonia being a common complication. While pneumococcal vaccines can prevent pneumococcal pneumonia and invasive pneumococcal disease, whether they can also prevent the severe in-hospital outcomes among patients hospitalized for influenza has [...] Read more.
Influenza is an important respiratory viral pathogen in adults, with secondary bacterial pneumonia being a common complication. While pneumococcal vaccines can prevent pneumococcal pneumonia and invasive pneumococcal disease, whether they can also prevent the severe in-hospital outcomes among patients hospitalized for influenza has not been examined. A territory-wide retrospective study was conducted in Hong Kong, which included all adult patients having chronic airway diseases (asthma, bronchiectasis, and chronic obstructive pulmonary disease) hospitalized for influenza and who had received seasonal influenza vaccine. The occurrence of secondary bacterial pneumonia, mortality, and other severe in-hospital outcomes were compared among subjects with or without pneumococcal vaccination. There was a total of 3066 eligible patients who were hospitalized for influenza in public hospitals in Hong Kong from 1 January 2016 to 30 June 2023. Completed pneumococcal vaccination with PSV23/PCV13 conferred protection against secondary bacterial pneumonia, all-cause mortality, and respiratory cause of mortality with adjusted odds ratios of 0.74 (95% CI = 0.57–0.95, p = 0.019), 0.12 (95% CI = 0.03–0.53, p = 0.005), and 0.04 (95% CI = 0.00–0.527, p = 0.0038), respectively. Full article
(This article belongs to the Special Issue Vaccines against Emerging Infectious Diseases)
►▼ Show Figures

Figure 1

16 pages, 4314 KiB  
Article
Single-Dose Intranasal Immunisation with Novel Chimeric H1N1 Expressing the Receptor-Binding Domain of SARS-CoV-2 Induces Robust Mucosal Immunity, Tissue-Resident Memory T Cells, and Heterologous Protection in Mice
by Donghong Wang, Yao Deng, Jianfang Zhou, Wen Wang, Baoying Huang, Wenling Wang, Lan Wei, Jiao Ren, Ruiwen Han, Jialuo Bing, Chengcheng Zhai, Xiaoyan Guo and Wenjie Tan
Vaccines 2023, 11(9), 1453; https://doi.org/10.3390/vaccines11091453 - 4 Sep 2023
Cited by 1 | Viewed by 1766
Abstract
Current COVID-19 vaccines can effectively reduce disease severity and hospitalisation; however, they are not considerably effective in preventing infection and transmission. In this context, mucosal vaccines are pertinent to prevent SARS-CoV-2 infection and spread. In this study, we generated a replication-competent recombinant chimeric [...] Read more.
Current COVID-19 vaccines can effectively reduce disease severity and hospitalisation; however, they are not considerably effective in preventing infection and transmission. In this context, mucosal vaccines are pertinent to prevent SARS-CoV-2 infection and spread. In this study, we generated a replication-competent recombinant chimeric influenza A virus (IAV) expressing the receptor-binding domain (RBD) of a SARS-CoV-2 prototype in the C-terminus of the neuraminidase (NA) of A/Puerto Rico/08/1934 H1N1 (PR8). The remaining seven segments from A/WSN/1933 H1N1 (WSN) were named PR8NARBD/WSN. We observed that the recombinant virus with the WSN backbone demonstrated improved expression of NA and RBD. A single intranasal dose of PR8NARBD/WSN(103PFU) in mice generated robust mucosal immunity, neutralising antibodies, cellular immunity, and tissue-resident memory T cells specific to SARS-CoV-2 and IAV. Importantly, immunisation with PR8NARBD/WSN viruses effectively protected mice against lethal challenges with H1N1, H3N2 IAV, and SARS-CoV-2 Beta variant and significantly reduced lung viral loads. Overall, our research demonstrates the promising potential of PR8NARBD/WSN as an attractive vaccine against emerging SARS-CoV-2 variants and influenza A virus infections. Full article
(This article belongs to the Special Issue Vaccines against Emerging Infectious Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

38 pages, 1762 KiB  
Review
Human Tick-Borne Diseases and Advances in Anti-Tick Vaccine Approaches: A Comprehensive Review
by Marie-Edith Nepveu-Traversy, Hugues Fausther-Bovendo and George (Giorgi) Babuadze
Vaccines 2024, 12(2), 141; https://doi.org/10.3390/vaccines12020141 - 29 Jan 2024
Cited by 2 | Viewed by 3767
Abstract
This comprehensive review explores the field of anti-tick vaccines, addressing their significance in combating tick-borne diseases of public health concern. The main objectives are to provide a brief epidemiology of diseases affecting humans and a thorough understanding of tick biology, traditional tick control [...] Read more.
This comprehensive review explores the field of anti-tick vaccines, addressing their significance in combating tick-borne diseases of public health concern. The main objectives are to provide a brief epidemiology of diseases affecting humans and a thorough understanding of tick biology, traditional tick control methods, the development and mechanisms of anti-tick vaccines, their efficacy in field applications, associated challenges, and future prospects. Tick-borne diseases (TBDs) pose a significant and escalating threat to global health and the livestock industries due to the widespread distribution of ticks and the multitude of pathogens they transmit. Traditional tick control methods, such as acaricides and repellents, have limitations, including environmental concerns and the emergence of tick resistance. Anti-tick vaccines offer a promising alternative by targeting specific tick proteins crucial for feeding and pathogen transmission. Developing vaccines with antigens based on these essential proteins is likely to disrupt these processes. Indeed, anti-tick vaccines have shown efficacy in laboratory and field trials successfully implemented in livestock, reducing the prevalence of TBDs. However, some challenges still remain, including vaccine efficacy on different hosts, polymorphisms in ticks of the same species, and the economic considerations of adopting large-scale vaccine strategies. Emerging technologies and approaches hold promise for improving anti-tick vaccine development and expanding their impact on public health and agriculture. Full article
(This article belongs to the Special Issue Vaccines against Emerging Infectious Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop